Cargando…

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients

Immunotherapy with checkpoint inhibitors (CPIs) strongly improved the outcome of metastatic melanoma patients. However, not all the patients respond to treatment and identification of prognostic biomarkers able to select responding patients is currently of outmost importance. Considering that develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carbone, Maria Luigia, Madonna, Gabriele, Capone, Alessia, Bove, Marianna, Mastroeni, Simona, Levati, Lauretta, Capone, Mariaelena, Ascierto, Paolo Antonio, De Galitiis, Federica, D’Atri, Stefania, Fortes, Cristina, Volpe, Elisabetta, Failla, Cristina Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971439/ https://www.ncbi.nlm.nih.gov/pubmed/35361879 http://dx.doi.org/10.1038/s41598-022-09373-9

Ejemplares similares

Melanoma and Vitiligo: In Good Company
por: Failla, Cristina Maria, et al.
Publicado: (2019)

Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
por: Carbone, Maria Luigia, et al.
Publicado: (2023)

Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma
por: Tosi, Anna, et al.
Publicado: (2021)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
por: Caporali, Simona, et al.
Publicado: (2012)

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
por: Levati, Lauretta, et al.
Publicado: (2022)

Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors
por: Cristiani, Costanza Maria, et al.
Publicado: (2022)

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017)

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
por: Caporali, Simona, et al.
Publicado: (2017)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015)

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
por: Atripaldi, Luigi, et al.
Publicado: (2021)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
por: Caporali, Simona, et al.
Publicado: (2019)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
por: Modestino, Luca, et al.
Publicado: (2023)

Interleukin role in the regulation of endothelial cell pathological activation
por: Carbone, Maria Luigia, et al.
Publicado: (2021)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer
por: Costantini, Susan, et al.
Publicado: (2023)

Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
por: Caporali, Simona, et al.
Publicado: (2015)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2013)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
por: Scognamiglio, Giosuè, et al.
Publicado: (2021)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma
por: Barbato, Anna, et al.
Publicado: (2021)

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding
por: Graziani, Grazia, et al.
Publicado: (2016)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2014)

Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1
por: Failla, Cristina M., et al.
Publicado: (2018)

Transcriptional Regulators of T Helper 17 Cell Differentiation in Health and Autoimmune Diseases
por: Capone, Alessia, et al.
Publicado: (2020)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma
por: Audrito, Valentina, et al.
Publicado: (2018)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
por: Capone, Mariaelena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kqgrhkh5krkr32ioooodb9hhqe